JPM Week – San Francisco
January 9, 2023
In the first global sharing of its innovative solution for anaphylaxis treatment, De Motu Cordis (DMC) reports progress on its dry powder inhaler (DPI) containing epinephrine (adrenaline) for inhaled anaphylaxis treatment.
DMC Chief Medical Officer, Professor John Fraser, shared progress and outcomes from Phase I clinical studies, where plasma epinephrine concentration reached Cmax 8 times faster compared to a widely used autoinjector.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
